PCV13 Recommended for High Risk Adults

6/20/2012
On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Pfizer) for adults 19 years and older with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants.
 
On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Pfizer) for adults 19 years and older with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants.  PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax, Merck & Co. Inc.), the vaccine recommended for the previously mentioned groups of adults since 1997. Additional information regarding the use of PPSV23 and PCV13 can be found in the following documents: Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23). Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5934a3.htm. On December 30, 2011, the Food and Drug Administration granted accelerated approval for Prevnar 13 for ALL adults over 50 years of age. For more detailed information, see: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm285431.htm?source=govdelivery


 
Headline Date Content Type CME